83 related articles for article (PubMed ID: 1393578)
1. Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action.
Kihara T; Ikeda M; Ibii N; Matsushita A
Brain Res; 1992 Aug; 588(2):270-6. PubMed ID: 1393578
[TBL] [Abstract][Full Text] [Related]
2. Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: an in vivo microdialysis study.
Kihara T; Ikeda M; Matsushita A
Brain Res; 1990 Jun; 519(1-2):44-9. PubMed ID: 2397417
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of ceruletide on haloperidol-induced catalepsy in rats.
Ibii N; Ikeda M; Takahara Y; Eigyo M; Akiyoshi T; Matsushita A
Peptides; 1989; 10(4):779-83. PubMed ID: 2587420
[TBL] [Abstract][Full Text] [Related]
4. Effects of systemically administered ceruletide on the in vivo release and metabolism of dopamine in the medial prefrontal cortex of awake, freely moving rats: an in vivo microdialysis study.
Hagino Y; Moroji T
Brain Res; 1994 Apr; 644(1):40-6. PubMed ID: 8032948
[TBL] [Abstract][Full Text] [Related]
5. Influence of potassium concentration in microdialysis perfusate on basal and stimulated striatal dopamine release: effect of ceruletide, a cholecystokinin-related peptide.
Kihara T; Ikeda M; Miyazaki H; Matsushita A
J Neurochem; 1993 Nov; 61(5):1859-64. PubMed ID: 8228999
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat.
Kihara T; Ikeda M; Matsubara K; Matsushita A
Eur J Pharmacol; 1993 Jan; 230(3):271-7. PubMed ID: 8440305
[TBL] [Abstract][Full Text] [Related]
7. Ceruletide suppresses endogenous dopamine release via vagal afferent system, studied by in vivo intracerebral dialysis.
Hamamura T; Kazahaya Y; Otsuki S
Brain Res; 1989 Mar; 483(1):78-83. PubMed ID: 2706512
[TBL] [Abstract][Full Text] [Related]
8. Effect of cerulein on in vivo release of acetylcholine from the rat striatum.
Shimoyama M; Kito S
Brain Res; 1989 Jul; 492(1-2):381-4. PubMed ID: 2752307
[TBL] [Abstract][Full Text] [Related]
9. Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex.
Etou K; Kuroki T; Kawahara T; Yonezawa Y; Tashiro N; Uchimura H
Pharmacol Biochem Behav; 1998 Dec; 61(4):427-34. PubMed ID: 9802838
[TBL] [Abstract][Full Text] [Related]
10. Effects of ceruletide and haloperidol on the hypothalamo-pituitary beta-endorphin system and brain beta-endorphin contents in the rat: with special reference to effects of ceruletide in chronically haloperidol-treated rats.
Hagino Y; Okuwa M; Moroji T
Neuropeptides; 1991 Jan; 18(1):1-14. PubMed ID: 2046884
[TBL] [Abstract][Full Text] [Related]
11. Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors.
Tanganelli S; Fuxe K; von Euler G; Agnati LF; Ferraro L; Ungerstedt U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):300-4. PubMed ID: 2280797
[TBL] [Abstract][Full Text] [Related]
12. Loxiglumide, L-364,718 and L-365,260 prevent the inhibition of spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rat peripherally administered with cholecystokinin-8S.
Kimura I; Wakasono S; Kimura M
Jpn J Pharmacol; 1995 May; 68(1):129-32. PubMed ID: 7494376
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.
Marshall FH; Barnes S; Pinnock RD; Hughes J
Br J Pharmacol; 1990 Apr; 99(4):845-8. PubMed ID: 2361176
[TBL] [Abstract][Full Text] [Related]
14. Ceruletide suppresses rotational behavior in lesioned rats via CCKA receptors.
Fujisawa M; Miyamoto O; Itano T; Tokuda M; Matsui H; Nagao S; Negi T; Hatase O
Eur J Pharmacol; 1993 Jul; 238(1):127-30. PubMed ID: 8405076
[TBL] [Abstract][Full Text] [Related]
15. Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex.
Cosi C; Altar AC; Wood PL
Eur J Pharmacol; 1989 Jun; 165(2-3):209-14. PubMed ID: 2776829
[TBL] [Abstract][Full Text] [Related]
16. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
Altar CA; Boyar WC
Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
[TBL] [Abstract][Full Text] [Related]
17. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity.
Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A
Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453
[TBL] [Abstract][Full Text] [Related]
18. The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons.
Minabe Y; Ashby CR; Wang RY
Brain Res; 1991 May; 549(1):151-4. PubMed ID: 1893248
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum.
Rakovska A
Neurosci Lett; 1995 Aug; 195(3):151-4. PubMed ID: 8584197
[TBL] [Abstract][Full Text] [Related]
20. Modulation of striatal aspartate and dynorphin B release by cholecystokinin (CCK-8) studied in vivo with microdialysis.
You ZB; Pettersson E; Herrera-Marschitz M; Hökfelt T; Terenius L; Nylander I; Goiny M; Hughes J; O'Connor WT; Ungerstedt U
Neuroreport; 1994 Nov; 5(17):2301-4. PubMed ID: 7881050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
